Literature DB >> 25947159

Immunology of protection from Ebola virus infection.

Philip R Krause1, Paula R Bryant2, Thomas Clark3, Walla Dempsey2, Erik Henchal4, Nelson L Michael5, Jason A Regules5, Marion F Gruber4.   

Abstract

A December 2014 meeting reviewed Ebola virus immunology relevant to vaccine development, including Ebola prevention, immunity, assay standardization, and regulatory considerations. Vaccinated humans appear to achieve immune responses comparable in magnitude with those associated with protection in nonhuman primates, suggesting that immunological data could be used to demonstrate vaccine efficacy.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25947159     DOI： 10.1126/scitranslmed.aaa8202

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  8 in total

Review 1.  What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.

Authors:  Hana Golding; Surender Khurana; Marina Zaitseva
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

2.  Prognostic Analysis of Patients with Ebola Virus Disease.

Authors:  Xin Zhang; Yihui Rong; Lijian Sun; Liming Liu; Haibin Su; Jian Zhang; Guangju Teng; Ning Du; Haoyang Chen; Yuan Fang; Wei Zhan; Alex B J Kanu; Sheku M Koroma; Bo Jin; Zhe Xu; Haihan Song
Journal:  PLoS Negl Trop Dis       Date:  2015-09-23

3.  T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.

Authors:  Christopher L Cooper; Karen A Martins; Sabrina M Stronsky; David P Langan; Jesse Steffens; Sean Van Tongeren; Sina Bavari
Journal:  Emerg Microbes Infect       Date:  2017-06-07       Impact factor: 7.163

4.  Contrasting academic and lay press print coverage of the 2013-2016 Ebola Virus Disease outbreak.

Authors:  Mark D Kieh; Elim M Cho; Ian A Myles
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

Review 5.  A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?

Authors:  Teresa Lambe; Georgina Bowyer; Katie J Ewer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-05-26       Impact factor: 6.237

6.  A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Authors:  Benoit Callendret; Jort Vellinga; Kerstin Wunderlich; Ariane Rodriguez; Robin Steigerwald; Ulrike Dirmeier; Cedric Cheminay; Ariane Volkmann; Trevor Brasel; Ricardo Carrion; Luis D Giavedoni; Jean L Patterson; Chad E Mire; Thomas W Geisbert; Jay W Hooper; Mo Weijtens; Jutta Hartkoorn-Pasma; Jerome Custers; Maria Grazia Pau; Hanneke Schuitemaker; Roland Zahn
Journal:  PLoS One       Date:  2018-02-20       Impact factor: 3.240

7.  Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.

Authors:  Ariel Sobarzo; Spencer W Stonier; Olga Radinsky; Sigal Gelkop; Ana I Kuehne; Avishay Edri; Andrew S Herbert; Shlomit Fedida-Metula; Julius Julian Lutwama; Victoria Yavelsky; Claytus Davis; Angel Porgador; John M Dye; Leslie Lobel
Journal:  EBioMedicine       Date:  2019-07-17       Impact factor: 8.143

Review 8.  Development of Pandemic Vaccines: ERVEBO Case Study.

Authors:  Jayanthi Wolf; Risat Jannat; Sheri Dubey; Sean Troth; Matthew T Onorato; Beth-Ann Coller; Mary E Hanson; Jakub K Simon
Journal:  Vaccines (Basel)       Date:  2021-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.